Item 7.01 Regulation FD Disclosure.

On January 14, 2021, Ziopharm Oncology, Inc. (the "Company") conducted a presentation at the 39th Annual J.P. Morgan Healthcare Conference. In addition, on January 14, 2021, the Company issued a press release announcing that James Huang has been elected the Chairman of the Company's Board of Directors (the "Board") and Heidi Hagen has been elected the Lead Independent Director of the Board.

A copy of the presentation and press release are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, respectively. The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.




(d)   Exhibits



Exhibit
  No.        Description

99.1           Presentation of Ziopharm Oncology, Inc. dated January 14, 2021.

99.2           Press Release of Ziopharm Oncology, Inc. dated January 14, 2021.

 104         Cover Page Interactive Data File (embedded within the Inline XBRL
             document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses